Comparison

Amelubant European Partner

Item no. HY-19304-50mg
Manufacturer MedChem Express
CASRN 346735-24-8
Amount 50 mg
Quantity options 100 mg 10 mM/1 mL 10 mg 1 ea 25 mg 50 mg 5 mg
Category
Type Inhibitors
Specific against other
Purity 99.11
Formula C33H34N2O5
Citations [1]Birke FW, et al. In vitro and in vivo pharmacological characterization of BIIL 284, a novel and potent leukotriene B(4) receptor antagonist. J Pharmacol Exp Ther. 2001 Apr;297(1):458-66.
Smiles CC(C1=CC=C(OCC2=CC(COC3=CC=C(C(NC(OCC)=O)=N)C=C3)=CC=C2)C=C1)(C4=CC=C(O)C=C4)C
ECLASS 10.1 32160490
ECLASS 11.0 32160490
UNSPSC 12000000
Alias BIIL 284
Shipping condition Room temperature
Available
Manufacturer - Type
Reference compound
Manufacturer - Applications
COVID-19-immunoregulation
Manufacturer - Targets
Leukotriene Receptor
Shipping Temperature
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight
538.63
Product Description
Amelubant (BIIL 284) is a potent, oral and long acting LTB4 receptor antagonist, negligibly binds to LTB4 receptor, with Kis of 221 nM and 230 nM in vital cells and membranes. Amelubant (BIIL 284) is a proagent of active metabolites BIIL 260 and BIIL 315. Anti-inflammatory activity[1].
Manufacturer - Research Area
Inflammation/Immunology
Solubility
DMSO : 100 mg/mL (ultrasonic)
Manufacturer - Pathway
GPCR/G Protein
Isoform
LTB4
Clinical information
Phase 2

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 50 mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close